I might have to do a deep dive on this stock. This is ridiculous!

It was supposed to be a best-in-class company with good growth and a high moat…

Instead, the stock collapsed nearly 40% in a single session after management slashed FY26 earnings guidance. What makes this interesting is that the core long-term thesis arguably still remains intact: Cochlear still controls over 50% global market share of hearring implants, benefits from massive switching costs, and has a recurring installed-base revenue stream from processor upgrades and accessories.